{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:55:14Z","timestamp":1792706114677,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejpb.2026.115058","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:27:04Z","timestamp":1774110424000},"page":"115058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Impact of post approval quantitative changes in excipient composition on nitrosamine formation: De-risking strategy"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem A.","family":"Charoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ahmad","family":"Untoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyaur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115058_b0005","first-page":"1","article-title":"Presence of nitrosamine impurities in medicinal products","volume":"72","author":"Sedlo","year":"2021","journal-title":"Arh. Hig. Rada Toksikol."},{"key":"10.1016\/j.ejpb.2026.115058_b0010","unstructured":"Food & Drug Administration (FDA), FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity, Press Release (2018). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity (accessed 25th July 2024)."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115058_b0015","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12249-019-1376-1","article-title":"Lesson Learnt from recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities","volume":"20","author":"Charoo","year":"2019","journal-title":"AAPS. Pharmsci. Tech."},{"key":"10.1016\/j.ejpb.2026.115058_b0020","doi-asserted-by":"crossref","unstructured":"Y. Li, S.S. Hecht. Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed, Int. J. Mol. Sci. 23 (2022) 4559. 16, https:\/\/doi.org\/10.3390\/ijms23094559.","DOI":"10.3390\/ijms23094559"},{"key":"10.1016\/j.ejpb.2026.115058_b0025","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N-nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejpb.2026.115058_b0030","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","article-title":"Nitrosamine contamination in pharmaceuticals: threat, impact, and control","volume":"110","author":"Tuesuwan","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115058_b0035","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","article-title":"Inhibition of N-nitrosamine formation in drug products: a model study","volume":"110","author":"Nanda","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115058_b0040","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/14740338.2021.1917547","article-title":"Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products","volume":"20","author":"Nasr","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejpb.2026.115058_b0045","unstructured":"ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (2017), https:\/\/database.ich.org\/sites\/default\/files\/M7_R1_Guideline.pdf (accessed 17th Nov 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121740","article-title":"Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite","volume":"620","author":"Schlingemann","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115058_b0055","unstructured":"Lhasa, Information on the Nitrites in Excipients database, (2021), https:\/\/www.lhasalimited.org\/Initiatives\/nitrites.htm (accessed 25th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0060","unstructured":"Food and Drug Administration (FDA), Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (1997), https:\/\/www.fda.gov\/media\/70956\/download (accessed 25th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0065","unstructured":"Food and Drug Administration (FDA), Guidance for Industry Immediate Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (1995), https:\/\/www.fda.gov\/media\/70949\/download (accessed 25th July 25th 2024)."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115058_b0070","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.jmedchem.0c02120","article-title":"Critical Analysis of Drug Product recalls due to Nitrosamine Impurities","volume":"64","author":"Bharate","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2026.115058_b0075","unstructured":"Food and Drug Administration (FDA), Search List of Recalled Angiotensin II Receptor Blockers (ARBs) including Valsartan, Losartan and Irbesartan (2021), https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and (accessed 17th Nov 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0080","unstructured":"Food and Drug Administration (FDA), Specific list of recalled metformin products (2022) https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/search-list-recalled-metformin-products (accessed 17th Nov 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0085","unstructured":"Food and Drug Administration (FDA), Drug Recalls (2024), https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/drug-recalls (accessed 5th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0090","unstructured":"Glucophage\u00ae SR 500 mg, 750 mg and 1000 mg prolonged release tablets. metformin hydrochloride, Prescribing information \u2013 UK (2017) (accessed 25th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0095","unstructured":"Summary of product characteristics (SmPC), Glucophage SR 1000 mg prolonged release tablets (2022), https:\/\/www.medicines.org.uk\/emc\/product\/10723\/smpc#about-medicine (accessed 25th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0100","article-title":"NDMA analytics in metformin products: Comparison of methods and pitfalls","volume":"168","author":"Fritzsche","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115058_b0105","unstructured":"Summary of product characteristics (SmPC), Cozaar 50 mg Film-Coated Tablets (2022), https:\/\/www.medicines.org.uk\/emc\/product\/7799\/smpc#gref (accessed 25th July 2024)."},{"issue":"8","key":"10.1016\/j.ejpb.2026.115058_b0110","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3390\/pharmaceutics15082015","article-title":"Modeling the Impact of Excipients selection on Nitrosamine Formation towards Risk Mitigation","volume":"15","author":"Berardi","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.ejpb.2026.115058_b0115","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","article-title":"A Nitrite Excipient Database: a Useful Tool to support N-Nitrosamine Risk Assessments for Drug Products","volume":"112","author":"Boetzel","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115058_b0120","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.xphs.2023.01.027","article-title":"N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations","volume":"112","author":"Moser","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115058_b0125","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115058_b0130","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","article-title":"Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water","volume":"24","author":"Ashworth","year":"2020","journal-title":"Org. Proc. Res. Dev."},{"key":"10.1016\/j.ejpb.2026.115058_b0135","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N-nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u2019opez-Rodr\u00edguez","year":"2020","journal-title":"Org. Proc. Res. Dev."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115058_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-023-02523-w","article-title":"Nitroso Impurities in Drug Products: an Overview of Risk Assessment, Regulatory Milieu, and Control Strategy","volume":"24","author":"Charoo","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2026.115058_b0145","unstructured":"Food and Drug Administration (FDA), Control of Nitrosamine Impurities in Human Drugs Guidance for Industry (2021), https:\/\/www.fda.gov\/media\/141720\/download (accessed 25th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0150","doi-asserted-by":"crossref","unstructured":"J. Dilebo, T. Gabriel, An overview of factors affecting superdisintegrants functionalities. Int. J. Pharm. Sci. Nanotech. 12 (2019), 4355-61, https:\/\/doi.org\/10.37285\/ijpsn.2019.12.1.1.","DOI":"10.37285\/ijpsn.2019.12.1.1"},{"key":"10.1016\/j.ejpb.2026.115058_b0155","unstructured":"EMA. Nitrosamine impurities (2021), https:\/\/ www. ema. europa.eu\/en\/human- regulatory\/post- authorisation\/referral-procedures\/nitrosamine-impurities (accessed 10th Jan 2022)."},{"key":"10.1016\/j.ejpb.2026.115058_b0160","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/jnci\/50.4.1055","article-title":"Ascorbic acid blocking of aminopyrine nitrosation in NZO\/BL mice","volume":"50","author":"Greenblatt","year":"1973","journal-title":"J. Natl Cancer Inst."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115058_b0165","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1073\/pnas.70.3.747","article-title":"Protective effect of ascorbic acid on hepatotoxicity caused by sodium nitrite plus aminopyrine","volume":"70","author":"Kamm","year":"1973","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.ejpb.2026.115058_b0170","series-title":"Autooxidation in Food and Biological Systems","article-title":"Antioxidants as blocking agents against nitrosamine formation","author":"Mergens","year":"1980"},{"key":"10.1016\/j.ejpb.2026.115058_b0175","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/jf980130f","article-title":"Reaction of ferulic acid with nitrite: formation of 7-hydroxy 6-methoxy-1,2(4H)-benzoxazin-4-one","volume":"46","author":"Rousseau","year":"1998","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejpb.2026.115058_b0180","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","article-title":"Inhibition of N-Nitrosamine Formation in Drug Products: a Model Study","volume":"110(12(","author":"Nanda","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115058_b0185","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1248\/cpb.c20-00431","article-title":"Temperature-dependent formation of N- nitrosodimethylamine during the storage of ranitidine reagent powders and tablets","volume":"68","author":"Abe","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2026.115058_b0190","unstructured":"Food & Drug Administration. Laboratory analysis of ranitidine and nizatidine products. Laboratory Tests (2019). https:\/\/ www. fda. gov\/ drugs\/ drugsafety- and- availability\/laboratory-tests-ranitidine. (accessed 1st Dec 2020)."},{"key":"10.1016\/j.ejpb.2026.115058_b0195","series-title":"No. 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products (2023)","article-title":"Questions and answers for marketing authorisation holders\/applicants on the CHMP opinion for the Article 5(3) of Regulation (EC)","author":"European Medicines Agency (EMA)","year":"2023"},{"key":"10.1016\/j.ejpb.2026.115058_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115648","article-title":"Parts per billion of nitrite in microcrystalline cellulose by ion chromatography mass spectrometry with isotope labeled internal standard","volume":"235","author":"Zhu","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115058_b0205","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0378-4347(94)00374-2","article-title":"Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their N-labeled analogs","volume":"661","author":"Tsikas","year":"1994","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"10.1016\/j.ejpb.2026.115058_b0210","article-title":"Nitrites as precursors of N-nitrosation in pharmaceutical samples \u2013 a trace level analysis","volume":"213","author":"Jakub","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115058_b0215","unstructured":"R. Leister. Risk mitigation of nitrosamines formation in drug products: Role of Excipients. Meggle, https:\/\/www.meggle-pharma.com\/files\/uploads\/21_Meggle_Whitepaper_Nitrosamin_WEB.pdf (accessed 30th July 2024)."},{"key":"10.1016\/j.ejpb.2026.115058_b0220","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1021\/acs.oprd.4c00115","article-title":"Quantification of nitrite in excipients and chemicals: a versatile and highly sensitive method using headspace gas chromatography coupled to mass spectrometry","volume":"28","author":"Baumann","year":"2024","journal-title":"Org. Proc. Res. Dev."},{"key":"10.1016\/j.ejpb.2026.115058_b0225","unstructured":"IFF, Nitrite content in hydroxypropyl methylcellulose, https:\/\/pharma.iff.com\/fileadmin\/user_upload\/Editor\/Images\/Products\/Dietary_Supplements\/METHOCEL_TM_\/Methocel_Nitrite.pdf (accessed 3rd July 2024)."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:30:38Z","timestamp":1782822638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"alternative-id":["S0939641126000792"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115058","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of post approval quantitative changes in excipient composition on nitrosamine formation: De-risking strategy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115058"}}